Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT05703386 Recruiting - Hypertension Clinical Trials

Imaging the Pathogenesis of Cerebral Small Vessel Disease

Start date: November 8, 2022
Phase:
Study type: Observational

Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.

NCT ID: NCT05703191 Recruiting - Clinical trials for Pulmonary Hypertension of Newborn

A Real-world Study of Nitric Oxide Generator and Delivery System

Start date: February 3, 2023
Phase:
Study type: Observational

The study is aimed to observe the efficacy and safety of Nitric Oxide Generator and Delivery System in Pulmonary Hypertension of Newborn in real clinical settings.

NCT ID: NCT05700903 Recruiting - Hypertension Clinical Trials

Contributions to Hypertension With Androgen Deprivation Therapy

ARCH
Start date: September 20, 2023
Phase: Phase 4
Study type: Interventional

This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.

NCT ID: NCT05699681 Recruiting - Clinical trials for Pulmonary Hypertension

Correlation of Right Atrial Strain With Pulmonary Hypertension, Right Ventricular Function And Outcome In Pediatric Patients

Start date: January 1, 2021
Phase:
Study type: Observational

This observational study aims to assess correlation of right atrial strain measured by two-dimensional speckle tracking echocardiography with intraoperatively measured pulmonary artery pressures, other indices of right ventricular function and short term postoperative outcome.

NCT ID: NCT05699486 Recruiting - Clinical trials for Pulmonary Hypertension

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery

Start date: October 23, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter study evaluating the dose, effect, safety and tolerability of intravenous PDNO infusion given to patients undergoing cardiopulmonary bypass (CPB) surgery with post-operative acute pulmonary hypertension (aPH).

NCT ID: NCT05698043 Completed - Clinical trials for Hypertension and Dyslipidemia

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)

NCT ID: NCT05693779 Withdrawn - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

Exercise Therapy After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

EXPECT-PH
Start date: May 2023
Phase: N/A
Study type: Interventional

This study is being completed to determine the feasibility and acceptability of completing a home-based, structured, low-to-moderate intensity exercise training program in chronic thromboembolic pulmonary hypertension (CTEPH) patients following surgical or percutaneous intervention. Eligible participants will be enrolled and have a 12 week home based exercise training program. The study team hypothesizes that: The following percentage of participants successfully complete the ramp-up phase of the exercise program: - Greater or equal to 70% at end of week 7 - Greater or equal to 80% at end of week 10 - Greater or equal to 90% at end of week 12 - Greater or equal to 80% of participants will both complete ≥1 week of maintenance phase exercise and complete 12 weeks of the exercise intervention. - Patients will have no adverse events, defined as syncope, worsening World Health Organization (WHO) functional class, pulmonary hypertension (PH) related hospitalization, or death, caused by the exercise intervention.

NCT ID: NCT05690009 Recruiting - Hypertension Clinical Trials

Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease

AURA
Start date: February 27, 2023
Phase:
Study type: Observational [Patient Registry]

Real clinical practice register of Albuminuria detection in patients with previously undiagnosed chronic kidney disease

NCT ID: NCT05689268 Completed - Cirrhosis Clinical Trials

EUS-PPG vs HVPG in Portal Hypertension

GRAPE
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the correlation of the calculated portal pressure gradient (PPG) obtained by direct portal and hepatic pressure measurements with a conventional 22 G needle guided by EUS and indirect portal vein pressure measurements using the interventional radiology based hepatic venous pressure gradient (HVPG) procedure.

NCT ID: NCT05688917 Completed - Obesity Clinical Trials

Green Coffee Effect on Metabolic Syndrome

Start date: September 3, 2020
Phase: N/A
Study type: Interventional

The present study aimed to investigate the effect of green coffee bean extract (GCBE) on the inflammatory biomarkers in obese patients with a metabolic syndrome via analyzing some inflammatory biomarkers as resistin, TNF-α, total sialic acid, homocysteine, high sensitivity C-reactive protein (hs-CRP) and anti-inflammatory cytokine, adiponectin